Cosmo Pharmaceuticals Receives Regulatory Green Light for Winlevi(R) in South Korea
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Approval of Winlevi®: Cosmo Pharmaceuticals has received approval from South Korea's Ministry of Food and Drug Safety for Winlevi® (clascoterone) cream 1% to treat acne vulgaris in patients aged twelve and older, marking a significant step in the company's dermatology expansion.
Innovative Mechanism and Collaboration: Winlevi® is the first topical acne treatment in over 40 years with a unique mechanism of action as a topical androgen-receptor inhibitor, and it is being commercialized in South Korea through a partnership with Hyundai Pharm Co., Ltd.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
